These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20009542)

  • 1. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
    Nathan PD; Vinayan A; Stott D; Juttla J; Goh V
    Cancer Biol Ther; 2010 Jan; 9(1):15-9. PubMed ID: 20009542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
    Smith AD; Lieber ML; Shah SN
    AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
    Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
    Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
    Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
    BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
    Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
    Haider MA; Vosough A; Khalvati F; Kiss A; Ganeshan B; Bjarnason GA
    Cancer Imaging; 2017 Jan; 17(1):4. PubMed ID: 28114978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.
    Ornstein MC; Wood L; Elson P; Allman K; Beach J; Martin A; Gilligan T; Garcia JA; Rini BI
    Clin Genitourin Cancer; 2017 Apr; 15(2):e275-e280. PubMed ID: 27625016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
    Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
    Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
    Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
    Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker.
    Goh V; Ganeshan B; Nathan P; Juttla JK; Vinayan A; Miles KA
    Radiology; 2011 Oct; 261(1):165-71. PubMed ID: 21813743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
    Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
    Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
    Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
    Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
    AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
    Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
    Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
    Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.